Active Broker’s Choice: Morgan Stanley (NYSE:MS), Dynavax Technologies Corporation (NASDAQ:DVAX)

Several matter pinch shares of Morgan Stanley (NYSE:MS) [Trend Analysis], as shares surging 0.62% to $42.09 with a share volume of 12.19 Million. Nancy King, global head of commodities trading at Morgan Stanley, has spent the last few years remodeling what used to be one of the most profitable units on Wall Street, by downsizing and focusing on smaller, smart trades for customers instead of the big, risky bets it used to make on its own account.

The shift in strategy, which has cut the size of Morgan Stanley’s commodities business by roughly two thirds, was largely forced on the bank by post-financial crisis regulations that banned banks from using their own money on potentially risky speculation, and increased capital requirements. The bank is “sticking their toe back into the market,” said Robert Pease, senior counsel at law firm Bracewell and a former commodity and energy market regulator. The stock is going forward its 52-week low with 102.59% and moving down from its 52-week high price with -1.06%. The float short ratio was 1.40%, as compared to sentiment indicator; Short Ratio was 1.64.

Shares of Dynavax Technologies Corporation (NASDAQ:DVAX) [Trend Analysis] runs in leading trade, it moving up 9.57% to traded at $5.15. The firm has price volatility of 10.39% for a week and 11.19% for a month. Its beta stands at 1.95 times. Dynavax announces clinical data from an ongoing Phase 1/2 trial of a combination of SD-101 and low-dose irradiation in the treatment of low-grade lymphoma at ASH 2016 (DVAX).

Key findings presented include: Of the 28 evaluable patients treated across all dose levels, 3 had a partial response (:PR) and1 had a complete response (CR) as measured by Cheson criteria.

Durable abscopal tumor shrinkage was observed in the majority of patients. Confirming observations in the dose escalation phase, the most common treatment-related treatment emergent adverse events (TEAEs) in the expansion phase were flu-like symptoms, consistent with the engagement of TLR9 and the induction of interferon-alpha.

Increases in CD8+ cells were observed in the injected tumor, and correlated with an increased abscopal tumor shrinkage Narrow down four to firm performance, its weekly performance was 11.96% and monthly performance was -44.02%. The stock price of DVAX is moving down from its 20 days moving average with -20.59% and isolated negatively from 50 days moving average with -42.02%.

 

About Blake Escott

Blake Escott holds junior writer position in SWR. Before joining Streetwise Report, he was a freelance content Writer. He has high-level copywriting experience and particularly experienced in proofreading and editing. He covers news about different companies including all US market sectors. Interests: Commodities, Energy stocks, Sector-wise Stocks analysis, Utilities

Leave a Reply

Your email address will not be published. Required fields are marked *